Payment overview · 2025
General Payments
$794.34
34 reported records · 18 companies
Healthcare provider profile · identity verified
Mark A Davis, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEWBERRY, SC · NPI 1457465916
Verified facts
What the public records show
CMS Open Payments records show Mark A Davis, MD received $794.34 in general payments during 2025 across 34 reported records.
Corcept Therapeutics accounted for 23.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 290 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $185.16 | 23.3% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $88.08 | 11.1% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $67.37 | 8.5% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $64.49 | 8.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $52.51 | 6.6% | 3 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $51.47 | 6.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.25 | 5.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.58 | 4.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $31.74 | 4.0% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $28.53 | 3.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $27.04 | 3.4% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $24.26 | 3.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.97 | 2.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.79 | 2.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.54 | 2.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.22 | 2.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.73 | 1.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.61 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $794.34 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $185.16 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $64.49 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $63.20 | 3 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $51.47 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $51.42 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.58 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $32.48 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $31.74 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.30 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $28.53 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $27.04 | 1 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.65 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.54 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.73 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 217 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 178 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 143 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
217 | 41 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
178 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
143 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
71 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
290 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 738 | 174 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 587 | 135 |
| Pantoprazole Sodium | Pantoprazole Sodium | 558 | 123 |
| Metformin Hcl | Metformin Hcl | 535 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 534 | 100 |
| Atorvastatin Calcium | Atorvastatin Calcium | 468 | 129 |
| Losartan Potassium | Losartan Potassium | 384 | 100 |
| Furosemide | Furosemide | 373 | 99 |
| Tamsulosin Hcl | Tamsulosin Hcl | 346 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 325 | 76 |
| Allopurinol | Allopurinol | 320 | 64 |
| Lisinopril | Lisinopril | 294 | 72 |
| Eliquis | Apixaban | 290 | 47 |
| Potassium Chloride | Potassium Chloride | 281 | 68 |
| Gabapentin | Gabapentin | 270 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 235 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 227 | 57 |
| Omeprazole | Omeprazole | 226 | 51 |
| Farxiga | Dapagliflozin Propanediol | 217 | 41 |
| Famotidine | Famotidine | 215 | 64 |
| Lorazepam | Lorazepam | 203 | 39 |
| Valsartan | Valsartan | 203 | 54 |
| Tramadol Hcl | Tramadol Hcl | 190 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 184 | 32 |
| Alprazolam | Alprazolam | 180 | 35 |
| Jardiance | Empagliflozin | 178 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 169 | 48 |
| Glimepiride | Glimepiride | 159 | 39 |
| Trazodone Hcl | Trazodone Hcl | 156 | 31 |
| Pregabalin | Pregabalin | 147 | 26 |
| Carvedilol | Carvedilol | 144 | 36 |
| Ozempic | Semaglutide | 143 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 36 |
| Donepezil Hcl | Donepezil Hcl | 137 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 126 | 27 |
| Sertraline Hcl | Sertraline Hcl | 126 | 28 |
| Torsemide | Torsemide | 126 | 28 |
| Alendronate Sodium | Alendronate Sodium | 124 | 27 |
| Montelukast Sodium | Montelukast Sodium | 122 | 35 |
| Finasteride | Finasteride | 121 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 118 | 20 |
| Meloxicam | Meloxicam | 115 | 25 |
| Simvastatin | Simvastatin | 114 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 109 | 82 |
| Clopidogrel | Clopidogrel Bisulfate | 108 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 103 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 102 | 16 |
| Irbesartan | Irbesartan | 102 | 22 |
| Januvia | Sitagliptin Phosphate | 102 | 20 |
| Prednisone | Prednisone | 102 | 70 |
| Hydralazine Hcl | Hydralazine Hcl | 95 | 20 |
| Spironolactone | Spironolactone | 90 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 85 | 31 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 84 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 83 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 12 |
| Clonazepam | Clonazepam | 77 | 17 |
| Mirtazapine | Mirtazapine | 76 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 71 | 13 |
| Rybelsus | Semaglutide | 71 | 11 |
| Warfarin Sodium | Warfarin Sodium | 66 | 12 |
| Cefuroxime | Cefuroxime Axetil | 63 | 56 |
| Celecoxib | Celecoxib | 63 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 61 | 15 |
| Mounjaro | Tirzepatide | 61 | suppressed |
| Cilostazol | Cilostazol | 60 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 58 | 18 |
| Colchicine | Colchicine | 57 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 11 |
| Atenolol | Atenolol | 56 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 55 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 48 |
| Azithromycin | Azithromycin | 53 | 43 |
| Ezetimibe | Ezetimibe | 53 | 15 |
| Novolog Flexpen | Insulin Aspart | 53 | suppressed |
| Lovastatin | Lovastatin | 52 | 13 |
| Bumetanide | Bumetanide | 50 | suppressed |
| Chlorthalidone | Chlorthalidone | 50 | 11 |
| Entresto | Sacubitril/Valsartan | 50 | suppressed |
| Temazepam | Temazepam | 47 | 12 |
| Benazepril Hcl | Benazepril Hcl | 46 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 44 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 43 | 14 |
| Nateglinide | Nateglinide | 43 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 11 |
| Ibuprofen | Ibuprofen | 42 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | 13 |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Estradiol | Estradiol | 34 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Carisoprodol | Carisoprodol | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 23 |
| Risedronate Sodium | Risedronate Sodium | 33 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Telmisartan | Telmisartan | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 25 |
| Linzess | Linaclotide | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 16 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 15 |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Felodipine Er | Felodipine | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Kerendia | Finerenone | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Dexamethasone | Dexamethasone | 19 | 17 |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Indapamide | Indapamide | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | 12 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 14 |
| Humalog Kwikpen U-200 | Insulin Lispro | 16 | suppressed |
| Livalo | Pitavastatin Calcium | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 16 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Budesonide Dr | Budesonide | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Oxycontin | Oxycodone Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | 11 |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $794.34 · 34 records | Corcept Therapeutics | ABRYSVO, BREZTRI, Barostim Neo System, COMIRNATY, CRYSVITA, Cologuard Collection Kit, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, INJECTAFER, JARDIANCE, JOT DX, Kerendia, Korlym, OTEZLA, Ozempic, PREVNAR 20, PROLIA, REPATHA, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, VRAYLAR, XIFAXAN | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error